What signals are generated by anti-CD20 antibody therapy?

Current Hematologic Malignancy Reports

Volumn 1, Issue 4, 2006, Pages 205-213

  Bonavida, Benjamin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; ANTINEOPLASTIC AGENT; BAY 117085; BORTEZOMIB; CD20 ANTIBODY; CISPLATIN; DEHYDROXYMETHYLEPOXYQUINOMICIN; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GEMCITABINE; GW 5074; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; NAVELBINE; PACLITAXEL; PD 048059; PD 8098059; PICEATANNOL; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN INHIBITOR; PROTEIN KINASE B; RAF PROTEIN; RITUXIMAB; SN 50; UNCLASSIFIED DRUG; UO 126; VINBLASTINE;

APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL COMMUNICATION; CELL SURVIVAL; CHEMOSENSITIZATION; CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME INHIBITION; GENE OVEREXPRESSION; HUMAN; IN VIVO STUDY; MOLECULAR CLONING; MONOTHERAPY; NONHODGKIN LYMPHOMA; TREATMENT OUTCOME; WILD TYPE;

ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-X PROTEIN; CELL LINE, TUMOR; CLONE CELLS; CYTOTOXICITY, IMMUNOLOGIC; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION; HUMANS; IMMUNOTHERAPY; LYMPHOMA, NON-HODGKIN; MAP KINASE SIGNALING SYSTEM; NEOPLASM PROTEINS; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; YY1 TRANSCRIPTION FACTOR;

EID: 33846211135     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-006-0001-z     Document Type: Article

References (46)

1. Hainsworth JD: Prolonging remission with rituximab maintenance therapy. Semin Oncol 2004, 31(1 Suppl 2):17-21. This review describes clinical findings of prolongation of survival or remission in patients with non-Hodgkin's lymphoma (NHL) with rituximab maintenance therapy. The response rate of patients with untreated, indolent NHL who were first treated with rituximab followed by maintenance treatment improved from 47% after initial treatment to 73% after maintenance treatment.
2. Coiffier B: First-line treatment of follicular lymphoma in the era of monoclonal antibodies. Clin Adv Hematol Oncol 2005, 3:484-491. This review describes the outcome of patients with NHL who were treated with rituximab alone or in combination with chemotherapy. The combination treatment resulted in a higher complete response rate and longer time to progression than treatment with rituximab alone.
3. Jazirehi AR, Bonavida B: Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention [review]. Oncogens 2005, 24:2121-2143. This recent review is the first to describe the effect of rituximab treatment on cell signaling and the modification of survival signaling pathways by rituximab in the laboratory. It also describes gene products involved in resistance to chemotherapy and characterizes the mechanism of rituximab resistance.
4. Reff ME, Carner K, Chambers KS, et al.: Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994, 83:435-445.
5. Kennedy AD, Solga MD, Schuman TA, et al.: An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab. Blood 2003, 101:1071-1079.
6. Shan D, Ledbetter JA, Press OW: Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother 2000, 48:673-683.
7. Demidem A, Lam T, Alas S, et al.: Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997, 12:177-186.
8. Alas S, Emmanouilides C, Bonavida B: Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res 2001, 7:709-723.
9. Li Z, David G, Hung KW, et al.: Cdk5/p35 phosphorylates mSds3 and regulates mSds3-mediated repression of transcription. J Biol Chem 2004, 279:54438-54444.
10. Cragg MS, Walshe CA, Ivanov AO, Glennie MJ: The biology of CD20 and its potential as a target for mAb therapy [review]. Curr Dir Autoimmun 2005, 8:140-174. This extensive review describes the effect of rituximab treatment on the cell membrane lipid rafts and inhibition of cell signaling. In addition, it provides possible underlying mechanisms of responsiveness and unresponsiveness to rituximab.
11. Deans JP, Kalt L, Ledbetter JA, et al.: Association of 75/80-kDa phosphoproteins and the tyrosine kinases Lyn, Fyn, and Lck with the B cell molecule CD20. Evidence against involvement of the cytoplasmic regions of CD20. J Biol Chem 1995, 270:22632-22638.
12. Deans JP, Robbins SM, Polyak MJ, Savage JA: Rapid redistribution of CD20 to a low density detergent-insoluble membrane compartment. J Biol Chem 1998, 273:344-348.
13. Semac I, Palomba C, Kulangara K, et al.: Anti-CD20 therapeutic antibody rituximab modifies the functional organization of rafts/microdomains of B lymphoma cells. Cancer Res 2003, 63:534-540.
14. Jazirehi AR, Vega MI, Chatterjee D, et al.: Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab. Cancer Res 2004, 64:117-126. This study reveals for the first time that rituximab treatment of NHL cell lines inhibits the MEK1/2-ERK1/2 signaling pathways, resulting in inhibition of AP-1 and Bcl-x transcription. These events led to chemosensitization. This study also demonstrates that rituximab treatment resulted in the induction of RKIP expression and participated in the inhibition of the MEK1/2 signaling pathway.
15. Bezombes C, Grazide S, Garret C, et al.: Rituximab anti-proliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains. Blood 2004, 104:1166-1173. This study describes the mechanisms by which rituximab inhibits cell growth and demonstrates a rituximab-induced rapid and transient increase in acid sphingomyelinase activity. This was accompanied by ceramide generation in raft microdomains and resulted in the induction of cyclic-dependent kinase inhibitors involved in cell proliferation.
16. Deans JP, Li H, Polyak MJ: CD20-mediated apoptosis: signalling through lipid rafts. Immunology 2002, 107:176-182.
17. Borsellino N, Belldegrun A, Bonavida B: Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res 1995, 55:4633-4639.
18. Mizutani Y, Bonavida B, Nio Y, Yoshida O: Overcoming TNF-alpha and drug resistance of human renal cell carcinoma cells by treatment with pentoxifylline in combination with TNF-alpha or drugs: the role of TNF-alpha mRNA downregulation in tumor cell sensitization. J Urol 1994, 151:1697-1702.
19. Su L, David M: Distinct mechanisms of STAT phosphorylation via the interferon-alpha/beta receptor. Selective inhibition of STAT3 and STAT5 by piceatannol. J Biol Chem 2000, 275:12661-12666.
20. Blay JY, Burdin N, Rousset F, et al.: Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor. Blood 1993, 82:2169-2174.
21. Alas S, Ng CP, Bonavida B: Rituximab modifies the cisplatin- mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma. Clin Cancer Res 2002, 8:836-845.
22. Vega MI, Huerta-Yepaz S, Garban H, et al.: Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance. Oncogene 2004, 23:3530-3540. This study shows that rituximab-induced inhibition of the IL-10-IL-10R loop in 2F7 DL-DCL resulted from inhibition of p38 MAPK and Sp1, which inhibited IL-10 transcription. Thus, rituximab-mediated inhibition of the p38 MAPK/Sp1/IL10-IL-10R/pSTAT3/Bcl-2 pathway was responsible for chemosensitization.
23. Jazirehi AR, Gan XH, De Vos S, et al: Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther 2003, 2:1183-1193.
24. Xerri L, Parc P, Brousset P, et al.: Predominant expression of the long isoform of Bcl-x (Bcl-xL) in human lymphomas. Br J Haematol 1996, 92:900-906.
25. Yeung K, Seitz T, Li S, et al.: Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature 1999, 401:173-177.
26. Yeung K, Janosch P, McFerran B, et al.: Mechanism of suppression of the Raf/MEK/extracellular signal-regulated kinase pathway by the raf kinase inhibitor protein. Mol Cell Biol 2000, 20:3079-3085.
27. Ghosh S, Karin M: Missing pieces in the NF-κB puzzle [review]. Cell 2002, 109:81-96.
28. Dixit V, Mak TW: NF-κB signaling. Many roads lead to Madrid. Cell 2002, 111:615-619.
29. Yeung KC, Rose DW, Dhillon AS, et al.: Raf kinase inhibitor protein interacts with NF-κB-inducing kinase and TAK1 and inhibits NF-κB activation. Mol Cell Biol 2001, 21:7207-7217.
30. Vivanco I, Sawyers CL: The phosphatidylinositol 3-kinase AKT pathway in human cancer [review]. Nat Rev Cancer 2002, 2:489-501.
31. Suzuki E, Palladino M, Bonavida B: Rituximab sensitizes resistant B-NHL cell lines to proteasome inhibitor NPI-0052-induced apoptosis [abstract]. Proc Amer Assoc Cancer Res 2006, 47:Abstract 5429.
32. Hongo F, Garban H, Huerta-Yepez S, et al.: Inhibition of the transcription factor yin yang 1 activity by S-nitrosation. Biochem Biophys Res Commun 2005, 336:692-701.
33. Huerta-Yepez S, Vega M, Jazirehi A, et al.: Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-κB and inhibition of Bcl-xl expression. Oncogene 2004, 23:4993-5003.
34. Garban HJ, Bonavida B: Nitric oxide inhibits the transcription repressor yin-yang 1 binding activity at the silencer region of the Fas promoter: a pivotal role for nitric oxide in the up-regulation of Fas gene expression in human tumor cells. J Immunol 2001, 167:75-81.
35. Barnhart BC, Alappat EC, Peter ME: The CD95 type I/type II model. Semin Immunol 2003, 15:185-193.
36. Vega MI, Jazirehi AR, Huerta-Yepez S, Bonavida B: Rituximab-induced inhibition of YY1 and Bcl-xL expression in Ramos non-Hodgkin's lymphoma cell line via inhibition of NF-kappa B activity: role of YY1 and Bcl-xL in Fas resistance and chemoresistance, respectively. J Immunol 2005, 175:2174-2183. This study describes for the first time the effect of rituximab-induced upregulation of the death receptor Fas via inhibition of the transcription repressor YY1, resulting in the sensitization of NHL cells to Fas ligand-induced apoptosis. This finding suggests a novel mechanism of rituximab-mediated effect in vivo.
37. Kennedy AD, Beum PV, Solga MD, et al.: Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol 2004, 172:3280-3288.
38. Haidar JH, Shamseddine A, Salem Z, et al.: Loss of CD20 expression in relapsed lymphomas after rituximab therapy. Eur J Hematol 2003, 70:330-332.
39. Manshouri T, Do KA, Wang X, et al.: Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 2003, 101:2507-2513.
40. Jazirehi AR, Bonavida B: Cellular and molecular characterization of rituximab-resistant CD20+ NHL Ramos (Ramos RR1) and Daudi (Daudi RR1) clones: development of cross-resistance to cytotoxic stimuli [abstract]. Blood (ASH Annual Meeting Abstracts) 2004, 104:Abstract 3410. This study describes the generation of rituximab-resistant clones as a model to mimic rituximab unresponsiveness in patients. It demonstrates that the resistant clones fail to be triggered by rituximab and cannot be chemosensitized by rituximab. However, the clones can be sensitized by pharmacologic inhibitors of the ERK1/2 and NF-κB pathways.
41. Jazirehi AR, Bonavida B: Sensitization of rituximab-sensitive and rituximab-resistant B-NHL cell lines/clones to TRAIL-induced apoptosis by bortezomib and NF-κB inhibitors [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:Abstract 1514. This study demonstrates that rituximab treatment of NHL cell lines upregulates the expression of the death receptor DR5 and sensitizes the cells to TRAIL-induced apoptosis. In addition, treatment with bortezomib and NF-κB inhibitors mimics rituximab and sensitizes the cells to TRAIL-induced apoptosis.
42. Vega M, Jazirehi AR, Bonavida B: New targets identified for therapeutic intervention in the reversal of rituximab and drug resistant AIDS-B-NHL [abstract]. Proc Amer Assoc Cancer Res 2006, 47:Abstract 5424.
43. Jazirehi AR, Bezombes C, Laurant G, et al.: Characteristics of rituximab-resistant B-NHL clones in lipid raft microdomains and cell signaling [abstract]. Proc Amer Assoc Cancer Res 2006, 47:Abstract 4657.
44. Alas SA, Bonavida B: Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clin Cancer Res 2003, 9:316-326.
45. Emmanouilides C, Jazirehi A, Bonavida B: Rituximab-mediated sensitization of B-non-Hodgkin's lymphoma (NHL) to cytotoxicity induced by paclitaxel, gemcitabine, and vinorelbine. Cancer Biother Radiopharm 2002, 17:621-630.
46. Jazirehi AR, Huerta-Yepez S, Cheng G, Bonavida B: Rituximab (chimeric anti-CD20 mAb) inhibits the constitutive NIK/IKK/IκB/NF-κB signaling pathway in non-Hodgkin's lymphoma (NHL) B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Res 2005, 65:264-276. This report describes for the first time rituximab-induces inhibition of the NF-κB pathway leading to inhibition of Bcl-x transcription and expression and leading to chemosensitization.